J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan

Introduction: On the basis of the IMpower133 trial, atezolizumab plus carboplatin and etoposide (CE) is approved as first-line treatment for extensive-stage (ES)-SCLC. The J-TAIL-2 study evaluated atezolizumab plus CE in routine clinical practice settings. Methods: J-TAIL-2 was a prospective, multic...

Full description

Saved in:
Bibliographic Details
Main Authors: Eisaku Miyauchi, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Nobuyuki Katakami, MD, PhD, Masahide Oki, MD, PhD, Takashi Kijima, MD, PhD, Kenichi Chikamori, MD, PhD, Kazumi Nishino, MD, PhD, Yuki Kobayashi, MS, Asako Miwa, BA, Misa Tanaka, MS, Akihiko Gemma, PhD
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:JTO Clinical and Research Reports
Subjects:
Extensive-stage small cell lung cancer
Atezolizumab
Immune checkpoint inhibitor
Observational study
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432400153X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items